FDA/CDC

FDA declines dapagliflozin indication as adjunct for type 1 diabetes


 

The Food and Drug Administration has rejected AstraZeneca’s supplemental New Drug Application for the sodium-glucose cotransporter 2 inhibitor dapagliflozin (Farxiga) as an adjunct treatment to insulin in adult patients with type 1 diabetes.

The company said in a press statement that the FDA had issued a complete response letter regarding the application. No reason was given for the decision, but the company said it would work with the agency to discuss the next steps.

The once-daily therapy has been approved as both a monotherapy and combination therapy, as an adjunct to diet and exercise, for improving glycemic control in adults with type 2 diabetes who cannot achieve control with insulin alone. It also has additional demonstrated benefits of weight loss and reduction in blood pressure.

On March 25, 2019, the drug received its first approval for treatment of patients with type 1 diabetes when the European Commission gave it the green light for use in patients with a body mass index of 27 kg/m2 or more when insulin alone does not provide adequate glycemic control. Japan followed a few days later with its approval of the sodium-glucose cotransporter 2 inhibitor, also for type 1 disease in adults.

The approvals for type 1 diabetes in the European Union and Japan were based on data from the phase 3 DEPICT (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) trial program (DEPICT-1 and DEPICT-2), which showed that 5 mg dapagliflozin, taken daily as an oral adjunct to insulin in patients with hard-to-control type 1 disease, reduced blood glucose levels from baseline (the primary endpoint). Secondary endpoints – reductions in weight and total daily insulin use – were also achieved.

Dapagliflozin’s safety profile in the trials in patients with type 1 diabetes was consistent with that established in patients with type 2 disease. However, there was a higher number of cases of diabetic ketoacidosis events in patients who received dapagliflozin. Diabetic ketoacidosis is a known complication for adults with type 1 diabetes and is more prevalent in patients with type 1 disease than in those with type 2.

Recommended Reading

The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
MDedge Family Medicine
VOC-sniffing necklace may support early detection of hypoglycemia
MDedge Family Medicine
Mortality caused by chronic liver disease in setting of diabetes continues to rise
MDedge Family Medicine
Metformin linked to lower dementia risk in black patients
MDedge Family Medicine
SGLT2 inhibitors, GLP-1 RAs are effective, but costly in T2D
MDedge Family Medicine
Type 2 diabetes is particularly devastating in adolescents
MDedge Family Medicine
Using Obamacare authority, Trump aims to shift dialysis care to patients’ homes
MDedge Family Medicine
Low-fat dairy associated with decreased risk of type 2 diabetes
MDedge Family Medicine
BMI screening trigger for type 2 diabetes is unreliable for at-risk black, Hispanic adults
MDedge Family Medicine
CARMELINA confirms linagliptin’s renal, CV safety, but it’s still third-line for type 2 diabetes
MDedge Family Medicine